<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Med Life</journal-id>
      <journal-id journal-id-type="publisher-id">JMedLife</journal-id>
      <journal-title-group>
        <journal-title>Journal of Medicine and Life</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1844-122X</issn>
      <issn pub-type="epub">1844-3117</issn>
      <publisher>
        <publisher-name>Carol Davila University Press</publisher-name>
        <publisher-loc>Romania</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">20108484</article-id>
      <article-id pub-id-type="pmc">3018960</article-id>
      <article-id pub-id-type="publisher-id">JMedLife-01-74</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Presentation</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Myeloma cells with asurophilic granules &#x2013; an unusual morphological variant &#x2013; case presentation
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Vl&#x103;d&#x103;reanu</surname>
            <given-names>AM</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>C&#xEE;&#x15F;leanu</surname>
            <given-names>D</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Derve&#x15F;teanu</surname>
            <given-names>M</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Onisai</surname>
            <given-names>M</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bumbea</surname>
            <given-names>Horia</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rade&#x15F;i</surname>
            <given-names>S</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Begu</surname>
            <given-names>M</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>B&#x103;lu&#x163;&#x103;</surname>
            <given-names>C</given-names>
          </name>
        </contrib>
        <aff>
          <institution>University of Medicine and Pharmacy Carol Davila &#x2013; Clinic of Hematology Universitary Emergency Hospital 
Bucharest</institution>
          <country>Romania</country>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp><bold>Correspondence to:</bold> Ana Maria Vl&#x103;d&#x103;reanu, Chairman, Assistant Professor Department of Hematology, 
Emergency Universitary Hospital Bucharest,Splaiul Independentei 169, Bucharest 050098, Romania</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <volume>1</volume>
      <issue>1</issue>
      <fpage>74</fpage>
      <lpage>96</lpage>
      <permissions>
        <copyright-statement>&#xA9;Carol Davila University Press</copyright-statement>
        <copyright-year>2008</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
          <license-p>This is an open-access article
distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in
any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p> We present the case of an 80&#x2013;year&#x2013;old man who was admitted for anemia, back pain and progressive weakness. After a 
workup of clinical and laboratory data, the final diagnosis was multiple myeloma. The bone marrow aspirate revealed 53% myeloma 
cells with peculiar and rare  morphological features: numerous large asurophilic&#x2013;bright red granules &#x2013; mucopolizaccharides 
and immunoglobulins secreted and  accumulated in the endoplasmic reticulum, typically known as Russel bodies. </p>
      </abstract>
      <kwd-group>
        <kwd>plasma cells</kwd>
        <kwd>asurophilic granules</kwd>
        <kwd>Russel bodies</kwd>
        <kwd>Dutcher bodies</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="Introduction" id="sec1-1">
      <title>Introduction</title>
      <p>Multiple myeloma is a neoplastic plasma cell dyscrasia characterized by monoclonal proliferation of plasma cells with their 
accumulation in the bone marrow [<xref ref-type="bibr" rid="R1">1</xref>]. The malignant plasma cells produce an immunoglobulin (Ig) or 
protein M, a homogeneous Ig, formed of only one type of heavy chain and one type of light chain (kappa or lambda); the 
immunohistochemical particularities of this Ig establish the clinical features of the disease. </p>
      <p>Diagnostic criteria for multiple myeloma include: more than 10% atypical plasma cells in the bone marrow, a monoclonal 
immunoglobulin in the serum or light chains in the urine and the presence of osteolytic lesions
[<xref ref-type="bibr" rid="R2">2</xref>].</p>
      <p>Anemia, renal insufficiency, hypercalcemia, metabolic dysfunctions and infections are all clinical features of the disease, with 
prognostic value [<xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>]. </p>
      <sec>
        <title>Myeloma cells have different morphological variants</title>
        <p>Usually, bone marrow aspirate shows clusters with a variable number of plasma cells; this underlines the need of careful examination 
of more than one smear. The bone marrow involvement is usually &#x2018;focal&#x2019;. Solitary plasma cell infiltration appears in rare 
cases [<xref ref-type="bibr" rid="R2">2</xref>].</p>
        <p>Myeloma cells have distinct morphological criteria: [<xref ref-type="bibr" rid="R2">2</xref>, 
<xref ref-type="bibr" rid="R5">5</xref>,<xref ref-type="bibr" rid="R6">6</xref>]</p>
        <p>Myeloma cells are larger than reactive plasma cells, with high nucleo/cytoplasmic ratio. The nucleus is displaced from the center of 
the cell, with nodular chromatin pattern; some of the cells may present a nucleolus and a perinuclear clear zone. Multi &#x2013; or 
binucleated plasma cells are present. The cytoplasm is basophilic with large intracytoplasmic inclusions (mucopolysaccharides and 
immunoglobulins secreted and accumulated in the endoplasmic reticulum), known as Russell bodies, resembling a bunch of grapes 
[<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R7">7</xref>]. 
Dutcher bodies are PAS positive intranuclear inclusions seen in plasma cells. In myeloma, there is often discordance between nucleus and 
cytoplasm, the former appearing immature and the latter highly differentiated. There is often a high polymorphism &#x2013; there are seen both 
abnormal plasma cells, and transitional forms &#x2013; lymphoplasmacytoid &#x2013; cells with intermediate features between lymphocytes 
and plasma cells [<xref ref-type="bibr" rid="R2">2</xref>]. </p>
        <p>Disorders to be considered in the differential diagnosis of multiple myeloma include monoclonal gammopathy of undetermined 
significance (MGUS), smoldering myeloma, plasma cell leukemia, bone solitary plasmacytoma, extramedullar plasmacytoma, primary 
amyloidosis, chronic  lymphocytic leukemia and bone marrow metastasis [<xref ref-type="bibr" rid="R1">1</xref>].</p>
        <p>The median survival period after diagnosis is approximately three years. Among the prognostic factors identified in this disease are: 
plasma cell proliferation index, &#x3B2;2 microglobulin level, C reactive protein, creatinine, lactate dehydrogenase (LDH), low serum albumin, 
plasmablast morphology [<xref ref-type="bibr" rid="R8">8</xref>], abnormal karyotypes (the complete deletion of chromosome 13) or t (4; 
14), t (14;16) translocation [<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R4">4</xref>]. 
Although there is virtually no prospect of a cure with current therapies (VMCP, VAD regimens etc, plus bisphosphonates) 
[<xref ref-type="bibr" rid="R9"/>&#x2013;<xref ref-type="bibr" rid="R13">13</xref>], there are several options under investigation 
that include combinations of drugs such as Thalidomide, Bortezomib and CC &#x2013; 5013
 &#x2013; Lenalidomide. [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R14">14</xref>, 
 <xref ref-type="bibr" rid="R15">15</xref>] Several groups have used VAD followed by intensive myeloablative therapy with autologous 
 marrow transplantation in younger patients [<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R16">16</xref>].</p>
      </sec>
    </sec>
    <sec sec-type=" Full case presentation " id="sec1-2">
      <title> Full case presentation</title>
      <p>We present the case of an 80 &#x2013; year &#x2013; old man, P.N. with percutaneous vertebroplasty in February 2007; he was in his 
usual state of health until two months prior to presentation, when he began to complain of back pain and progressive weakness.	</p>
      <p>A complete blood cell count (CBC) revealed normochromic, normocytic anemia (hemoglobin 7.1 g/dl), rouleaux formation was appreciated 
on peripheral blood smear, biological inflammatory syndrome (ESR 60mm/hour, C reactive protein &#x2013; positive), high lactate 
dehydrogenase (LDH 301U/l), creatinine 3.97mg/dl, BUN 157mg/dl, hypokaliemia (K 3.6mmols/l), hypercalcemia (Ca &#x2013; 10.31mg/dl), 
hyperuricemia (8mg/dl). Serum protein electrophoresis detected a monoclonal peak limited to the gamma region of the electrophoretic strip
(albumin 30%, alpha1 = 2.9%, alpha2 = 14.4%; beta = 8.7%; gamma = 44%); 
immunoelectrophoresis showed high values of IgG (35g/l), with low IgA (0.295g/l) and IgM (0.497g/l); urine immunofixation detected Bence 
Jones proteinuria. </p>
      <p>	Bone marrow aspiration was performed and revealed a hypercellular bone marrow with increased plasma cells (53%) with decreased
granulocytic and erythrocytic components, with a slight megaloblastic deviation, and with present thrombocytogenic megakaryocytes 
(<xref ref-type="fig" rid="F1">Fig 1</xref>)</p>
      <fig id="F1" position="float">
        <label>Fig 1</label>
        <caption>
          <p>Clusters of plasma cells can be seen throughout this view of the aspirate &#x2013; P.N. case (BM &#x2013;MGG, objective 
20X)</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g001"/>
      </fig>
      <p>Flow cytometry analysis of the bone marrow aspirate is not included in the diagnostic criteria of multiple myeloma; in this case, no 
aberrant phenotype was noted - the profile of plasma cells was CD 38+ CD 138+ CD 56+(favorable prognostic 
factor) and CD 19 - (<xref ref-type="fig" rid="F2">Fig 2</xref>,<xref ref-type="fig" rid="F3">Fig 3</xref>).</p>
      <fig id="F2" position="float">
        <label>Fig 2</label>
        <caption>
          <p>Dot&#x2013;plot histograms: plasma cells (purple) positive for CD 38, CD 138, CD 56 and negative for CD 19 (BD 
Facs&#x2013;Calibur, Software CellQuest version 3.3) &#x2013;  P.N. case.</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g002"/>
      </fig>
      <fig id="F3" position="float">
        <label>Fig 3</label>
        <caption>
          <p>Dot &#x2013;  plot histograms: plasma cells (purple) positive for CD 38, CD 138, CD 56 and negative for CD 19 (BD 
Facs &#x2013;  Calibur, Software CellQuest version 3.3) &#x2013;  P.N. case.</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g003"/>
      </fig>
      <p>The particular aspect of this case resides in the morphological features of the myeloma plasma cells 
(<xref ref-type="fig" rid="F4">Fig 4</xref> to <xref ref-type="fig" rid="F7">Fig 7</xref>). These are large cells arranged in 
clusters, with basophilic cytoplasm, with excentrically placed nucleus and a perinuclear clear zone. The chromatin has a particular 
nodular pattern; an inconstant nucleolus may be observed. Plasma cells had numerous large azurophilic &#x2013; bright red granules 
&#x2013; mucopolysaccharides and immunoglobulins secreted and accumulated in the endoplasmic reticulum, typically known as Russel bodies 
[<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>]. </p>
      <fig id="F4" position="float">
        <label>Fig 4</label>
        <caption>
          <p>Clusters of plasma cells with azurophilic granules (MO &#x2013; MGG, 100x 
objective) &#x2013;P.N. case</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g004"/>
      </fig>
      <fig id="F5" position="float">
        <label>Fig 5</label>
        <caption>
          <p>Plasma cells with numerous azurophilic granules that tend to cover the nucleus, in some cases with
cohesive appearance (Auer rods&#x2013;like) &#x2013; P.N. case</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g005"/>
      </fig>
      <fig id="F6" position="float">
        <label>Fig 6</label>
        <caption>
          <p>Plasma cells with numerous azurophilic granules, one binucleated, some granules have foamy aspect (MO 
&#x2013; MGG, 100x objective) &#x2013; P.N. case
</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g006"/>
      </fig>
      <fig id="F7" position="float">
        <label>Fig 7</label>
        <caption>
          <p>Plasma cells with numerous azurophilic granules, some granules have foamy aspect (MO &#x2013; MGG, 
100x objective) &#x2013; P.N. case</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g007"/>
      </fig>
      <p>The investigations were completed with X &#x2013; rays of the skull which showed multiple lytic cranial lesions and diffuse osteoporosis 
(<xref ref-type="fig" rid="F8">Fig 8</xref>). Spinal MRI scan identified of compression fracture of T12, L1, L2 with diffuse 
osteoporosis (<xref ref-type="fig" rid="F9">Fig 9</xref>).</p>
      <fig id="F8" position="float">
        <label>Fig 8</label>
        <caption>
          <p>Skull x &#x2013; ray showing multiple lytic areas &#x2013; P.N. case</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g008"/>
      </fig>
      <fig id="F9" position="float">
        <label>Fig 9</label>
        <caption>
          <p>Spinal MRI scan &#x2013; compression fracture of T12, L1, L2 with collapsed plateau &#x2013; P.N. case
</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g009"/>
      </fig>
      <p>The final diagnosis was Multiple Myeloma IgG Kappa stage III B; this was established according to Salmon&#x2013;Durie Staging System 
[<xref ref-type="bibr" rid="R17">17</xref>] in the presence of major criteria: 53% myeloma plasma cells in bone marrow, monoclonal
protein peak in serum, osteolytic lesions, corroborated with: anemia, renal failure, hypercalcemia. The multiple myeloma was complicated 
with compression fracture, secondary anemia, and possibly secondary amyloidosis. The renal failure may have a combined etiology: 
amyloidosis, myeloma kidney, excess NSAIDs treatment for back pain. </p>
      <p>With an obvious diagnosis, the differential diagnosis was easy to establish [<xref ref-type="bibr" rid="R1">1</xref>, 
<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R3">3</xref>], including: a) monoclonal gammapathy of 
undetermined significance (MGUS) and b) smoldering myeloma, both with monoclonal immunoglobulin in the serum less than 3g/dl, &gt; 
10% plasma cells in bone marrow, no evidence of myeloma end &#x2013; organ damage &#x2013; anemia, renal failure, hypercalcemia, 
lytic lesions; c) Waldenstrom's macroglobulinemia with IgM paraprotein peak and lymphoplasmacytic bone marrow infiltration 
[<xref ref-type="bibr" rid="R1">1</xref>]. </p>
      <p>The patient's prognosis is unfavorable [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R4">4</xref>] 
because of multiple associated factors: age, aggressive onset of disease &#x2013; with 
complications (acute renal failure, multiple lytic lesions, vertebral destructions that needed surgical intervention), associated cardiac
pathology which limits the possible therapeutic regimens, other biological factors with prognostic value &#x2013; severe anemia, 
increased LDH, positive PCR. We mention that neither the percentage of plasma cell involvement of the bone marrow, nor the morphological 
aspect of plasma cells represent prognostic factors &#x2013; except for the case when plasmablasts are observed, or when plasma cells 
appear on the peripheral blood smear (PBS) [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R4">4</xref>].</p>
    </sec>
    <sec sec-type="Discussion" id="sec1-3">
      <title>Discussion</title>
      <p> Multiple morphological variants of plasma cells are described [<xref ref-type="bibr" rid="R2">2</xref>,
 <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>]</p>
      <list list-type="bullet">
        <list-item>
          <p>Plasma cells with abundant eosinophilic cytoplasm because of the presence of immunoglobulins as bright red granules 
&#x2013; Flame Cells, frequently associated with IgA myeloma; however, they can also be associated with other types of myeloma.
</p>
        </list-item>
        <list-item>
          <p>Plasma cells with globular inclusions (Russell bodies) in their cytoplasm &#x2013; Mott cells &#x2013; resembling a bunch 
of grapes</p>
        </list-item>
        <list-item>
          <p>Plasmablast &#x2013; large cells with a very large nucleus and prominent nucleolus (adverse prognostic factor)
</p>
        </list-item>
        <list-item>
          <p>Multiple intracellular mitosis and abnormal plasma cells with large nucleus</p>
        </list-item>
      </list>
      <p>Plasma cells have a great variety of intracytoplasmic or intranuclear inclusions [<xref ref-type="bibr" rid="R2">2</xref>,
 <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>]: Russell 
bodies (mucopolysaccharides and immunoglobulins secreted and accumulated in the endoplasmic reticulum), immunoglobulin granules and large
vacuoles. These different globular intracytoplasmic inclusions are often mistaken for Auer rods or liposarcoma cells, or even 
adenocarcinoma cells &#x2013; the typical aspect is of signet ring cells [<xref ref-type="bibr" rid="R6">6</xref>]. </p>
      <p>Because of the peculiar morphological aspect of plasma cells presented in this case (numerous large azurophilic &#x2013; bright red 
granules), we considered necessary to have a careful differential diagnosis with other morphological variants 
[<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>,
<xref ref-type="bibr" rid="R7">7</xref>] &#x2013; typical plasma cells (<xref ref-type="fig" rid="F10">Fig 10</xref>, <xref ref-type="fig" rid="F11">
Fig 11</xref>), sarcoma plasma cells like 
(<xref ref-type="fig" rid="F13">Fig 13</xref>), plasmablasts (<xref ref-type="fig" rid="F14">Fig 14</xref>,
<xref ref-type="fig" rid="F15">Fig 15</xref>), foamy plasma cells (<xref ref-type="fig" rid="F15">Fig 15</xref>), 
flame cells (<xref ref-type="fig" rid="F16">Fig 16</xref>), Russell bodies (<xref ref-type="fig" rid="F12">Fig 12</xref>) 
and reactive plasma cells. </p>
      <p>The morphological variants of plasma cells are presented below in <xref ref-type="table" rid="T1">Table 1</xref>:</p>
      <table-wrap id="T1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Different morphological aspects of plasma cells</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="center" rowspan="1" colspan="1">
                <italic>Type</italic>
              </th>
              <th align="center" rowspan="1" colspan="1">
                <italic>Characteristics</italic>
              </th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" rowspan="1" colspan="1">Plasma cells with or without anaplastic</td>
              <td align="center" rowspan="1" colspan="1">high incidence</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">nucleo/cytoplasmic asynchronism or dysplastic characteristics;</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">nucleolus plasma cells</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">anaplastic morphological type includes: large nucleus, polymorphism, morphological aspects resembling immunoblastic 
lymphoma</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">Small/lymphocytic cells</td>
              <td align="center" rowspan="1" colspan="1">central nucleus, abundant or moderate basophilic cytoplasm;</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">small incidence</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">Lobulated/ folded/monocytoid/ convoluted</td>
              <td align="center" rowspan="1" colspan="1">small incidence</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">lobulated nucleus and multiple irregularities</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">Flame Cells</td>
              <td align="center" rowspan="1" colspan="1">polymorphic cells with eosinophilic cytoplasm (Flame Cells)</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">torn cytoplasm cells</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1"/>
              <td align="center" rowspan="1" colspan="1">multinucleated cells, associated with IgA myeloma, but also present in other myeloma types</td>
            </tr>
            <tr>
              <td align="center" rowspan="1" colspan="1">Plasmablast</td>
              <td align="center" rowspan="1" colspan="1">more than 2% blasts with high nucleo/cytoplasmic ratio, diffuse chromatin, variable nucleolus</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="F10" position="float">
        <label>Fig 10</label>
        <caption>
          <p>Typical plasma cells &#x2013; cluster cells, eccentrically placed nucleus, nodular chromatin, 
basophilic cytoplasm, perinuclear clear zone, some multinucleated, others with nucleolus (B.M. &#x2013; MGG, 100x objective) &#x2013; 
images from &#x2018;Diagnosis of Hematologic Malignancies &#x2013; Atlas Notes and Images&#x2019;, Ana Maria Vl&#x103;d&#x103;reanu, Carol Davila 
Universitary Publishing House, Bucharest, 2007 &#x2013; Hematology Department &#x2013; Emergency Universitary Hospital Bucharest, with 
the author's permission</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g0010"/>
      </fig>
      <fig id="F11" position="float">
        <label>Fig 11</label>
        <caption>
          <p>Typical plasma cells (nucleus displaced from the center, nodular chromatin, basophilic cytoplasm, a 
perinuclear clear zone, some multinucleated) and lymphoplasmacytoid cells (reduced basophilic cytoplasm, with high nucleo/cytoplasmic 
ratio) &#x2013; (B.M. &#x2013; MGG, 100x objective) &#x2013; image from &#x2018;Diagnosis of Hematologic Malignancies &#x2013; Atlas 
Notes and Images&#x2019;, Ana Maria Vl&#x103;d&#x103;reanu, Carol Davila Universitary Publishing House, Bucharest, 2007 &#x2013; Hematology 
Department &#x2013; Emergency Universitary Hospital Bucharest, with the author's permission</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g0011"/>
      </fig>
      <fig id="F12" position="float">
        <label>Fig 12</label>
        <caption>
          <p>Plasma cells with Russell rods (B.M. &#x2013; MGG, 100x objective) &#x2013; image from &#x2018;Diagnosis of
 Hematologic Malignancies &#x2013; Atlas Notes and Images&#x2019;, Ana Maria Vl&#x103;d&#x103;reanu, Carol Davila Universitary Publishing House, 
Bucharest, 2007 &#x2013; Hematology Department &#x2013; Emergency Universitary Hospital Bucharest, with the author's permission
</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g0012"/>
      </fig>
      <fig id="F13" position="float">
        <label>Fig 13</label>
        <caption>
          <p>Plasma cell sarcoma like (B.M. &#x2013; MGG, 100x objective) &#x2013; image from &#x2018;Diagnosis of 
Hematologic Malignancies &#x2013; Atlas Notes and Images&#x2019;, Ana Maria Vl&#x103;d&#x103;reanu, Carol Davila Universitary Publishing House, 
Bucharest, 2007 &#x2013; Hematology Department &#x2013; Emergency Universitary Hospital Bucharest, with the author's permission
</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g0013"/>
      </fig>
      <fig id="F14" position="float">
        <label>Fig 14</label>
        <caption>
          <p>Plasmablasts &#x2013; high nucleo/cytoplasmatic ratio, some with nucleolus (P.B.S. &#x2013; MGG, 100x
 objective) &#x2013; images from &#x2018;Diagnosis of Hematologic Malignancies &#x2013; Atlas Notes and Images&#x2019;, Ana Maria 
Vl&#x103;d&#x103;reanu, Carol Davila Universitary Publishing House, Bucharest, 2007 &#x2013; Hematology Department &#x2013; Emergency Universitary 
Hospital Bucharest, with the author's permission</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g0014"/>
      </fig>
      <fig id="F15" position="float">
        <label>Fig 15</label>
        <caption>
          <p>Foamy plasma cells, plasmablasts with high nucleo/cytoplasmic ratio (B.M. &#x2013; MGG, 100x objective &#x2013; images 
from the cases diagnosed in the Hematology Department &#x2013; Emergency Universitary Hospital Bucharest)</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g0015"/>
      </fig>
      <fig id="F16" position="float">
        <label>Fig 16</label>
        <caption>
          <p>Flame plasma cell (B.M. &#x2013; MGG, 100x objective &#x2013; images from the cases diagnosed in the Hematology Department &#x2013; 
Emergency Universitary Hospital Bucharest)</p>
        </caption>
        <graphic xlink:href="JMedLife-01-74-g0016"/>
      </fig>
      <p>There is a classification of multiple myeloma based on morphology, with important implications in evolution and prognosis </p>
      <list list-type="bullet">
        <list-item>
          <p>Reduced malignancy MM: plasmocytic type</p>
          <list list-type="bullet">
            <list-item>
              <p>Small cells</p>
            </list-item>
          </list>
        </list-item>
        <list-item>
          <p>Intermediate malignancy MM: folded type</p>
          <list list-type="bullet">
            <list-item>
              <p>Polymorphous type</p>
            </list-item>
            <list-item>
              <p>Asynchronic type</p>
            </list-item>
          </list>
        </list-item>
        <list-item>
          <p>High malignancy MM: plasmablastic type.</p>
        </list-item>
      </list>
      <p>There are situations when it is necessary to make a differential diagnosis between plasma cells and blast cells in acute leukemia, and
other hematopoietic precursors &#x2013; osteoblast &#x2013; or nonhematopoietic cells (bone marrow metastasis) 
[<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>,]</p>
    </sec>
    <sec sec-type="Conclusions" id="sec1-4">
      <title>Conclusions</title>
      <p>The presented case illustrates the necessary diagnostic steps, a typical combination of clinical features and laboratory tests. </p>
      <p>It is a clear diagnosis: IgG Kappa multiple myeloma stage III B with compression fractures of T12, L1, L2, secondary anemia, possibly 
secondary amyloidosis and renal failure.</p>
      <p>The unusual aspect of this case is the morphological facet of myeloma cells &#x2013; with numerous large azurophilic&#x2013;bright red
granules; this characteristic, in the light of the multiple associated complications, may be regarded as an unfavorable prognostic 
factor in this particular case. </p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Kyle</surname>
              <given-names>Ra</given-names>
            </name>
            <name>
              <surname>Rajkumar</surname>
              <given-names>SV</given-names>
            </name>
          </person-group>
          <article-title>Plasma cell disorders.
</article-title>
          <source>Cecil textbook of medicine</source>
          <year>2004</year>
          <publisher-loc>Philadelphia</publisher-loc>
          <publisher-name>W.B. Saunders</publisher-name>
          <fpage>1184</fpage>
          <lpage>1195</lpage>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Vl&#x103;d&#x103;reanu</surname>
              <given-names>AM</given-names>
            </name>
          </person-group>
          <source>Diagnosticul hemopatiilor maligne in note si imagini de atlas</source>
          <year>2007</year>
          <publisher-loc>Bucuresti</publisher-loc>
          <publisher-name>Editura Universitara Carol Davila</publisher-name>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>International Myeloma Working Group</surname>
            </name>
          </person-group>
          <article-title> Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.</article-title>
          <source>Br J Haematol</source>
          <year>2003</year>
          <volume>121</volume>
          <fpage>749</fpage>
          <lpage>757</lpage>
          <pub-id pub-id-type="pmid">12780789</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajkumar</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Greipp</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Prognostic factors in multiple myeloma.</article-title>
          <source>Hematol Oncol Clin North Am</source>
          <year>1999</year>
          <volume>13</volume>
          <fpage>1295</fpage>
          <lpage>1314</lpage>
          <pub-id pub-id-type="pmid">10626152</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Begemann</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <source>Praktische Hamatologie. Klinic. Therapie. Methodik</source>
          <year>1999</year>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>Georg Thieme Verlag</publisher-name>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Foucar</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <source>Bone Marrow Pathology: ASCP Integrative Hematopathology Series 2</source>
          <year>2001</year>
          <publisher-loc>Chicago</publisher-loc>
          <publisher-name>ASCP Press</publisher-name>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barlogie</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Alexanian</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pershouse</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Smallwood</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Cytoplasmic immunoglobulin content in multiple myeloma.</article-title>
          <source>J Clin Invest</source>
          <year>1985</year>
          <volume>76</volume>
          <fpage>765</fpage>
          <lpage>769</lpage>
          <pub-id pub-id-type="pmid">2411762</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Graham</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Bernier</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
          <article-title>The bone marrow in multiple myeloma: correlation of plasma cell ultrastructure and clinical state. </article-title>
          <source>Medicine</source>
          <year>1975</year>
          <volume>54</volume>
          <fpage>225</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="pmid">167264</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pavlovsky</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Saslavsky</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tezanos Pinto</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in 
untreated multiple myeloma.</article-title>
          <source>J Clin Oncol</source>
          <year>1984</year>
          <volume>2</volume>
          <fpage>836</fpage>
          <lpage>840</lpage>
          <pub-id pub-id-type="pmid">6376722</pub-id>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Monconduit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Menard</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Michaux</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>VAD or VMBCP in severe multiple myeloma: the Groupe d'Etudes et de Recherche sur le Myelome (GERM).</article-title>
          <source>Br J Haematol</source>
          <year>1992</year>
          <volume>80</volume>
          <fpage>199</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">1550777</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alexanian</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Barlogie</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tucker</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>VAD based regimens as primary treatment for multiple myeloma.</article-title>
          <source>Am J Hematol</source>
          <year>1990</year>
          <fpage>33</fpage>
          <lpage>86</lpage>
          <lpage>89</lpage>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajkumar</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Gertz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Kyle</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Greipp</surname>
              <given-names>PR</given-names>
            </name>
          </person-group>
          <article-title>Current therapy for multiple myeloma.</article-title>
          <source>Mayo Clin Proc</source>
          <year>2002</year>
          <volume>77</volume>
          <fpage>813</fpage>
          <lpage>822</lpage>
          <pub-id pub-id-type="pmid">12173715</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berenson</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Lichtenstein</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Porter</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of pamidronate treatment in reducing skeletal events in patients with advanced multiple myeloma. </article-title>
          <source>N Engl J Med</source>
          <year>1996</year>
          <volume>334</volume>
          <fpage>448</fpage>
          <lpage>493</lpage>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajkumar</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Gertz</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lacy</surname>
              <given-names>MQ</given-names>
            </name>
          </person-group>
          <article-title>Thalidomide as initial therapy for earlystage myeloma.</article-title>
          <source>Leukemia</source>
          <year>2003</year>
          <volume>17</volume>
          <fpage>775</fpage>
          <lpage>779</lpage>
          <pub-id pub-id-type="pmid">12682636</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weber</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rankin</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Gavino</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname> Delasalle</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Alexanian</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.</article-title>
          <source>J Clin Oncol</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>16</fpage>
          <lpage>19</lpage>
          <pub-id pub-id-type="pmid">12506164</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gahrton G, Tura S, Ljungman P</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ljungman</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Allogeneic bone marrow transplantation in multiple myeloma.
</article-title>
          <source>N Engl J Med</source>
          <year>1991</year>
          <volume>325</volume>
          <fpage>1267</fpage>
          <lpage>1273</lpage>
          <pub-id pub-id-type="pmid">1922221</pub-id>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greipp</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>San Miguel</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Durie</surname>
              <given-names>BG</given-names>
            </name>
          </person-group>
          <article-title>A new international staging system (ISS) for multiple myeloma (MM) from the International Myeloma Working Group.  
</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <fpage>190a</fpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
